Ncardia launches Cellistic™ — purpose-built to make large-scale allogeneic cell therapy production a reality today

Published on April 18, 2022

Ncardia launches CellisticTM, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.

Continue reading on website
Other news

Ncardia Launches Cellistic™ — Purpose-Built To Make Large-Scale Allogeneic Cell Therapy Production A Reality Today

April 18, 2022
Ncardia launches Cellistic™, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.GOSSELIES, BELGIUM (April 19, 2022) – Ncardia has launched a new business, Cellistic™, to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector

Reducing Health Disparities during National Minority Health Month

April 20, 2022
April is National Minority Health Month, and the Department of Health and Human Services Office of Minority Health is highlighting the key role individuals and organizations can play in helping to reduce health disparities and improve the health of racial and ethnic minorities and American Indian/Alaska Native communities. This year, the goal is the continued […]